atherosclerotic cardiovascular diseases,ASCVD
Conditions
Interventions
The observation group :Observation group: on the basis of the treatment regimen of the control group, combined with Xuezhikang treatment (600mg, twice a day, taken after breakfast and dinner, average
The control group:The control group was given moderate intensity statin to reduce lipid. Patients with underlying diseases such as hypertension or diabetes mellitus were treated with optimal individua
Sponsors
Zhengzhou Central Hospital Affiliated to Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) The age range was between 18 and 75 years; 2) The patients were confirmed to be at high risk of ASCVD; 3) The included patients had not used lipid-lowering drugs before, and had no contraindications to statins and Xuezhikang capsule; 4) All patients provided written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who had taken drugs that affected lipid metabolism in the past six months were excluded; 2) These patients were also excluded, such as those with severe liver and kidney dysfunction, poor blood glucose control, heart function class III-IV, severe valvular disease and other complex diseases, movement disorders and severe bone and joint diseases, severe infection, cancer, etc. ; 3) Patients with poor compliance were also excluded, such as not following the treatment plan, not taking medicine on time, unable to take medicine, etc. 4) Pregnant or lactating: The female patient is pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-C target attainment rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory indicators;cardio-pulmonary function;Volume and content of epicardial adipose tissue;Cardiovascular Outcomes; | — |
Countries
China
Contacts
Public ContactDongwei Wang
Zhengzhou Central Hospital Affiliated to Zhengzhou University
Outcome results
None listed